Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autoimmunity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Autoimmunity. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-001820-39 Sponsor Protocol Number: 1984 Start Date*: 2012-12-14
    Sponsor Name:Academic medical centre
    Full Title: Levothyroxine for euthyroid women with recurrent miscarriage and thyroid autoimmunity : a randomized controlled trial
    Medical condition: Thyroid autoimmunity is associated with recurrent miscarriage and preterm birth. Thyroid autoimmunity means there is a normal thyroid function, but presence of thyroid antibodies, thyroid peroxidas...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006220-40 Sponsor Protocol Number: 2022-0101-01 Start Date*: 2022-06-30
    Sponsor Name:Hvidovre Hospital, Department of Gynecology
    Full Title: Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity
    Medical condition: Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    21.0 100000004848 10069094 Thyroid peroxidase antibody positive LLT
    20.1 100000004848 10060326 Thyroglobulin antibody positive LLT
    22.1 100000004868 10072314 Pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002126-20 Sponsor Protocol Number: PID13341 Start Date*: 2018-08-13
    Sponsor Name:University of Oxford
    Full Title: Interleukin-2 therapy of Autoimmunity in Diabetes: ITAD
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    20.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-011152-22 Sponsor Protocol Number: GTG003.08 Start Date*: Information not available in EudraCT
    Sponsor Name:GENETHON
    Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome
    Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001996-21 Sponsor Protocol Number: LEPRE Start Date*: Information not available in EudraCT
    Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
    Full Title: Randomized clinical trial to evaluate the effects of different timing of levothyroxine administration in the management of hypothyroid pregnant women suffering from nausea and/or vomiting.
    Medical condition: SUBCLINICAL HYPOTHYROIDISM DURING PREGNANCY
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10000560 Acquired hypothyroidism other LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005346-58 Sponsor Protocol Number: RIMINI Start Date*: 2016-10-05
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI)
    Medical condition: Rejection rate, graft loss or poor graft function defined as eGFR<40 ml/min in patients with kidney transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006669-40 Sponsor Protocol Number: CURACTA Start Date*: 2023-04-20
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Plasma cell depletion as an approach to reset autoimmunity in rheumatoid arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004250-28 Sponsor Protocol Number: Psoriasi_Risa Start Date*: 2020-09-22
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: EXPLORING THE EFFECTS OF IL-23 INHIBITION BY RISANKIZUMAB ON PSORIASIS AUTOIMMUNITY.
    Medical condition: Moderate to severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000256-33 Sponsor Protocol Number: Ra-P-OCD-01 Start Date*: 2019-06-27
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
    Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000719-19 Sponsor Protocol Number: 09/100/10 Start Date*: 2011-05-05
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies. (TABLET: Thyroid AntiBodies and LEvoThyro...
    Medical condition: Thyroid autoimmunity and history of miscarriage or infertility.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002447-16 Sponsor Protocol Number: 111482 Start Date*: 2008-11-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma
    Medical condition: Patients with histologically proven stage IIIB or IIIC cutaneous melanoma with macroscopic lymph node involvement suitable for surgical resection. Macroscopic lymph node involvement is defined as c...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001496-11 Sponsor Protocol Number: 08020 Start Date*: 2010-01-15
    Sponsor Name:University of Nottingham
    Full Title: The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple Sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007484-16 Sponsor Protocol Number: DIAPREV/2008 Start Date*: 2009-02-27
    Sponsor Name:Helena Elding Larsson
    Full Title: DIAPREV-IT Diabetes Prevention Immune Tolerance. A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in ...
    Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003632-71 Sponsor Protocol Number: DEND/TIA Start Date*: 2014-07-14
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Dendritic cell-based immunotherapy for advanced solid tumours of children and young adults
    Medical condition: Children and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004366-10 Sponsor Protocol Number: 0642 Start Date*: 2019-05-24
    Sponsor Name:University of Leicester
    Full Title: A Phase 2 Placebo-controlled Double Blinded Study to Assess the Efficacy and Safety of Belimumab in Subjects with Immunoglobulin A Nephropathy (IgAN)
    Medical condition: Immunoglobulin A (IgA) nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-005078-25 Sponsor Protocol Number: CHUBX2019/59 Start Date*: 2023-01-25
    Sponsor Name:CHU de Bordeaux
    Full Title: Phase III randomized, multicenter open label study to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity.
    Medical condition: Mental and behavioral disorders (F00-F99)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000659-42 Sponsor Protocol Number: TN-22 Start Date*: 2019-03-12
    Sponsor Name:TrialNet Coordinating Center
    Full Title: HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1 DIABETES MELLITUS
    Medical condition: individuals at-risk for type 1 diabetes mellitus (T1D)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-003369-27 Sponsor Protocol Number: REGAIN Start Date*: 2016-07-01
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID)
    Medical condition: autoimmune enteropathy (AIE) in common variable immunodeficiency (CVID).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10021449 Immunodeficiency common variable PT
    19.0 100000004856 10017922 Gastroenteropathy NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003796-22 Sponsor Protocol Number: IFCT-1602 Start Date*: 2017-09-22
    Sponsor Name:IFCT
    Full Title: Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial
    Medical condition: Advanced non small cell lung cancer in VIH+ patient
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    20.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003211-57 Sponsor Protocol Number: CAIN457Q12301 Start Date*: 2020-03-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) NO (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) DE (Completed) SE (Prematurely Ended) DK (Prematurely Ended) GR (Completed) LV (Prematurely Ended) ES (Prematurely Ended) HR (Completed) FR (Completed) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 11:43:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA